TSHA Q3 2021 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena

TSHATaysha Gene Therapies, Inc.

$1B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$51M

Net Income

-$51M

EPS (Diluted)

$-1.35

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$36M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$241M

Total Liabilities

$101M

Stockholders' Equity

$140M

Cash & Equivalents

$189M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$51M	-$15M	-237.0%
Net Income	-$51M	-$15M	-240.3%